Paper Details

  1. Home
  2. Paper Details

[HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].

Author: GerkenG, HerzerK, JochumC, Papadopoulos-KöhnA, PaulA, TimmJ

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study reports the first experiences with telaprevir-based triple therapy in patients with hepatitis C virus (HCV) genotype 1 reinfection of the liver graft after transplantation.
Paper Details　
Original Abstract of the Article :
The management of hepatitis C virus (HCV) recurrence after liver transplantation (LTx) is a major challenge in patient care. For patients with HCV GT1, treatment standard with pegylated interferon (PEG-IFN) and ribavirin (RBV) has been augmented in 2011 by first generation protease inhibitors (PI), ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1055/s-0033-1349494

データ提供：米国国立医学図書館（NLM）

HCV Reinfection After Liver Transplantation: Management and Telaprevir-Based Triple Therapy

The management of hepatitis C virus (HCV) reinfection following liver transplantation (LTx), a challenging and complex medical scenario, is a key focus of this research. This study explores the effectiveness of telaprevir-based triple therapy, a novel treatment strategy, in addressing HCV reinfection in liver transplant recipients.

HCV Reinfection After Liver Transplantation: A New Approach to Treatment

This research, like a desert explorer seeking a new source of water, explores the potential of telaprevir-based triple therapy as a promising treatment strategy for HCV reinfection in liver transplant recipients. The study's findings suggest that this approach may offer a viable alternative to traditional therapies, improving outcomes for patients with HCV reinfection.

HCV Reinfection After Liver Transplantation: A Hope for Improved Outcomes

This research provides valuable insights into the management of HCV reinfection after liver transplantation, offering a potential new avenue for treatment. This study is like a beacon of hope in the desert, illuminating the potential of telaprevir-based triple therapy for improving outcomes for patients with HCV reinfection.

Dr.Camel's Conclusion

This study provides valuable information about the management of HCV reinfection after liver transplantation, highlighting the potential of telaprevir-based triple therapy as a promising treatment strategy. This research underscores the importance of ongoing research and development in the field of hepatology, leading to improved outcomes for patients with HCV reinfection.

Date :
  1. Date Completed 2013-11-07
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

24002874

DOI: Digital Object Identifier

10.1055/s-0033-1349494

Related Literature

Article Analysis
・Side Effects of boceprevir
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.